Compare Peloton Interactive Inc (PTON) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs Tango Therapeutics Inc. — how do they compare? Peloton Interactive Inc trades at $5.03 (market cap $2.30B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and Tango Therapeutics Inc. for 0 Days on average.
| PTON | TNGX | |
|---|---|---|
Market Cap | $2.30B | $3.75B |
Volume | 9,511,173 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $32.90 |
52-Week Low | $3.71 | $7.50 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $2.80B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton (PTON) trades at $5.06, down 1.56% today, showing mixed technical signals with a bullish overall rating but bearish moving averages. The company achieved its first profitable year in 2026 with $63M net income, though Q3 2026 earnings are pending. Revenue declined from $3.6B in 2022 to $2.4B in 2026, but profitability improved significantly with net margin turning positive. Recent product launches include new treadmills and AI features, signaling ongoing turnaround efforts.
PTON presents a speculative opportunity with analyst consensus price target of $8.00 (58% upside) and 50% buy ratings. Key risks include declining subscriber counts, high debt levels, and competitive pressures. The stock's valuation appears reasonable with P/S of 0.93, but negative shareholder equity and volatile cash flow history warrant caution. Near-term catalyst will be Q3 2026 earnings results versus expectations of $0.1098 EPS.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
